Novo Nordisk Buys British ‘Smart’ Insulin Diabetes Biotech in deal worth €702M

Status
Not open for further replies.
NN claims that stem cells may be ready for testing in 2 or 3 years; would think the authorities would be extremely wary of allowing stem cells to be introduced to the peritoneal cavity without exhaustive studies in other large mammals first- looks as though dogs and mice have been trialled so far. authorities would need to be completely satisfied that all of the cells could be retrieved on every occasion at the end of their useful life or the end of the trial. If it works it would represent definitive treatment for type 1 and 1.5 but the NHS does not have the capacity to perform all the laparoscopic surgery involved- would need to train diabetes physicians and CNS' s to perform the surgery, there are 300 000 type 1 in this country. On the other hand 10% of the NHS budget is presently spent on diabetes, much of it on complications.

as regards the glucose sensing molecule, it looks quite a large entity in relation to insulin. Insulin is about 50 amino acids, this molecule has many benzene rings and 0-, NH2 groups.
 
The techniques to do the laparoscopic insertion are pretty common and low tech, though. But the problem lies in getting it out again if things go awry. I don’t know where the implants have been inserted - do you?
 
each insertion/removal is not quite straightforward requires a general anaesthetic plus insufflation of the abdomen; don't know how the implant would be positioned in the peritoneal cavity. Don't know, if it works at all, how long it would last- they seem to suggest up to 24 months, possibly but that would mean a lot of operations particularly for those diagnosed at a young age.
 
not sure how practical stem cells at present would be;
not only would the NHS find it unaffordable but I read somewhere that the Novo Nordisk solution would require a 6 ft ribbon impregnated by stem cells and covered in gel to be implanted to control sugar in an adult male..
 
reports of a mit/novo/harvard joint venture soma ingestible insulin pill aimed at delivering basal doses/type2.. self-orientating millimeter applicator pill, still many years off probably.
 
yes... you spotted this first!

on a different tack it seems carbometrics are recruiting.
just been looking on carbometrics website the other university of Bristol spin-out company sister to ziylo under the same inventors, Destecroix, Davis et al,
seems their glucose binding molecules are produced by a 'streamlined scalable synthesis and are readily derivatised for bioconjugation and chemical synthesis'... they are also 'stable, versatile, offer unparalleled selectivity for glucose and function in the most complex biological mixtures' - presumably they mean blood.
looks promising after 7 months of collaboration between Novo and Ziylo.
 
Northerner said:
Novo Nordisk acquired the UK biotech Ziylo, which develops glucose-responsive insulin treatments for diabetes that act in response to changes in blood sugar levels.

The Danish big-pharma, which is already a big player in the diabetes space, acquired the full rights to Ziylo’s technology in a deal worth up to €702M ($800M). Novo will use the technology to develop so-called ‘smart’ insulin treatments for diabetics, designed to be taken once a day, that are only active when a patient’s blood sugar levels are too high or too low.

Smart insulin could lead to safer diabetes treatments by reducing the risk of low blood sugar or ‘hypos’, one of the main side effects of insulin therapy. Like conventional insulin, the technology is designed to keep high blood sugar, the hallmark symptom of diabetics, in check. But unlike normal insulin, it is designed to ‘switch off’ when blood glucose gets too low, or switch on when it gets too high.

https://labiotech.eu/medical/novo-nordisk-smart-insulin-diabetes/

This must be almost ready, they've been talking about smart insulin practically since I was diagnosed, and that was 10 years ago.... 😉 🙄
Click to expand...
Its 50 odd years since I have been hearing about a miracle :D. Something might happen ?
 
looking at Novo's capital markets day, they say that smart insulin will be in the clinic in 2020, rather earlier than expected when the partnership with Ziylo was set up, ie phase 1 trials so, if all goes well, will be on the market 3 years later in about 2023, will make millionaires of Professor Davis and his team at Ziylo and may be worthy of a Nobel prize if this gets to market and is a success as it will revolutionise treatment.
 
nn1845 novo nordisk 'smart' insulin in phase 1 in Germany as of September 30 according to Novo's 3rd quarter research update released today...still early days, have to hope this will be advanced to the next phases and, if successful, could revolutionise treatment....
 
Do you have shares in and or work for Novo, as this is the second time you have posted this today?
 
novonord said:
nn1845 novo nordisk 'smart' insulin in phase 1 in Germany as of September 30 according to Novo's 3rd quarter research update released today...still early days, have to hope this will be advanced to the next phases and, if successful, could revolutionise treatment....
Click to expand...
NN1845 is not based on Ziylo's molecule. It use "diboron" as glucose sensitive group, not Ziylo's GBM (glucose binding molecules). If NN1845 can "cover" all diet meals, fasting period and protect patients from hipoglycaemia (with no need for extra bolus insulin) it would be revolution in a treatment of diabetes and Novo will take all "insulin world market". Does anyone know when we can expect NN1845 to reach the market, if all goes well? In preclinical study NN1845 showed about 5 time stronger potency on 20mM than on 3 mM....witch is very promising!
 
The bit that impresses me is the ability to know and limit the insulin to a specific blood glucose range. It's really amazing stuff. If they combine the smart insulin with a smart glucogon release agent too, that would be perfect.
 
Amity Island said:
The bit that impresses me is the ability to know and limit the insulin to a specific blood glucose range. It's really amazing stuff. If they combine the smart insulin with a smart glucogon release agent too, that would be perfect.
Click to expand...
You do not need "smart glucagon" when you have glucose sensitive insulin with no or very low activity of insulin when blood glucose is low. Glucose sensitive insulin protect patient from hipoglycaemia.
 
NN'S GSI
 

Attachments

  • Screenshot_20210119-172110_Samsung Internet.jpg
    Screenshot_20210119-172110_Samsung Internet.jpg
    21.8 KB · Views: 7
  • Screenshot_20210119-172038_Samsung Internet.jpg
    Screenshot_20210119-172038_Samsung Internet.jpg
    27.1 KB · Views: 8
pinsulin said:
You do not need "smart glucagon" when you have glucose sensitive insulin with no or very low activity of insulin when blood glucose is low. Glucose sensitive insulin protect patient from hipoglycaemia.
Click to expand...
Hi @pinsulin

Thanks for your reply, do you know if that would mean one could excercise freely and not worry about hypo's, sounds amazing...so you wouldn't need to eat carbs to excercise?
 
Amity Island said:
Hi @pinsulin

Thanks for your reply, do you know if that would mean one could excercise freely and not worry about hypo's, sounds amazing...so you wouldn't need to eat carbs to excercise?
Click to expand...
You welcome....with GSI people with DM1 and advanced DM2 (on insulin) will live, work, excercize, sleep..etc free from hypos and from high blood sugar levels. The GSI will cover all fasting period (day and night), so, the main question is would GSI will cover all meals or some meals. GSI change it's potency about 5 times, so at low glucose levels insulin "work" with only about 20% of it's potency...
 
pinsulin said:
You welcome....with GSI people with DM1 and advanced DM2 (on insulin) will live, work, excercize, sleep..etc free from hypos and from high blood sugar levels. The GSI will cover all fasting period (day and night), so, the main question is would GSI will cover all meals or some meals. GSI change it's potency about 5 times, so at low glucose levels insulin "work" with only about 20% of it's potency...
Click to expand...
thanks for input on this thread: note that the phase 1 trial 68 subjects of NN1845 is complete, though was delayed somewhat by Covid complicating and delaying all trials: will have to wait a few months to see whether Novo will take the molecule further trial, phase 2, or start a phase 1 with the Ziylo construct or abandon the whole programme for the time being. Meanwhile, Eli Lilly has some interesting data on its Terzepatide for type 2.
 
Status
Not open for further replies.
Back
Top